Compare · JNJ vs UL
JNJ vs UL
Side-by-side comparison of Johnson & Johnson (JNJ) and Unilever PLC (UL): market cap, price performance, sector, and recent activity on the wire.
Summary
- JNJ operates in Health Care, while UL operates in Consumer Discretionary - the two are in different parts of the market.
- JNJ is the larger of the two at $574.10B, about 4.4x UL ($130.92B).
- JNJ has been more active in the news (10 items in the past 4 weeks vs 3 for UL).
- Both have 25 recent analyst ratings on file.
- Company
- Johnson & Johnson
- Unilever PLC
- Price
- $238.52+0.64%
- $58.64+1.84%
- Market cap
- $574.10B
- $130.92B
- 1M return
- +7.73%
- -
- 1Y return
- +53.66%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Package Goods/Cosmetics
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Unilever PLC
Unilever PLC operates as a fast-moving consumer goods company in Asia, Africa, the Middle East, Turkey, Russia, Ukraine, Belarus, the Americas, and Europe. It operates through Beauty & Personal Care, Foods & Refreshment, and Home Care segments. The Beauty & Personal Care segment provides skin care and hair care products, deodorants, and skin cleansing products under the Axe, Clear, Dove, Lifebuoy, Lux, Pond's, Rexona, Signal, Suave, Sunsilk, TRESemmé, and Vaseline brands. The Foods & Refreshment segment offers ice cream, soups, bouillons, seasonings, mayonnaise, ketchups, and tea categories under the Ben & Jerry's, Breyers, Brooke Bond, Heart (Wall's), Hellmann's, Knorr, Lipton, Magnum, The Vegetarian Butcher, and Unilever Food Solutions brands. The Home Care segment provides fabric solutions, and home care and hygiene products under the Cif, Omo, Persil, Domestos, Seventh Generation, and Sunlight brands. Unilever PLC was incorporated in 1894 and is based in London, the United Kingdom.
Latest JNJ
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
Latest UL
- SEC Form 425 filed by Unilever PLC
- SEC Form 6-K filed by Unilever PLC
- Unilever Investing $270M in Global Innovation Center in New Haven, Connecticut
- SEC Form 6-K filed by Unilever PLC
- SEC Form 6-K filed by Unilever PLC
- SEC Form 6-K filed by Unilever PLC
- SEC Form 6-K filed by Unilever PLC
- SEC Form 6-K filed by Unilever PLC
- SEC Form 6-K filed by Unilever PLC
- Unilever PLC upgraded by RBC Capital Mkts